After 10-year Partnership, Biocon’s Syngene, Bristol-Myers Squibb Establish Largest Research Center In Asia
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Bristol-Myers Squibb and Syngene - Biocon's contract research services arm - cemented a 10-year long association with the opening of what is called Asia's largest research facility near Bangalore. Syngene was established in 1994 and was the first to offer contract research services out of India. Syngene has now grown to become Biocon's fastest growing arm and has research alliances with Novartis and Merck
You may also be interested in...
AstraZeneca-BMS Diabetes Deal Done: What’s Next On Biocon’s Oral Insulin?
AstraZeneca has declined an option agreement from Bristol-Myers Squibb on Indian drug maker Biocon’s oral insulin, raising questions about the fate of the candidate Biocon hopes will be a blockbuster.
Rift In Eli Lilly-Cadila Alliance? Partners Mum But R&D Deal May Have Been Called Off
Eli Lilly and India’s Cadila break up what was to be a six-year CV discovery alliance.
Bristol-Myers Squibb Plans To Make India Its Global Pharma Innovation Hub
HYDERABAD, India - Bristol-Myers Squibb may not be as aggressive as its larger multinational competitors in playing the generics or the branded generics card, but the company best known for blockbusters like Abilify (aripiprazole) and Plavix (clopidogrel) has brought under sharp focus partnership-based research for developing innovative drugs in India